Thursday, 20 June 2019

Medanta sets new benchmark of clinical excellence

14 December 2018 | News

Medanta receives first international benchmark for cyberKnife & tomotherapy in India.

In continuation of its commitment to bringing world-class healthcare to all citizens, Medanta-The Medicity’s Cancer Institute met the exacting  international metrics of Postal Dosimetry Audit for CyberKnife and Tomotherapy. The audit is conjointly conducted by World Health Organisation and the International Atomic Energy Agency to optimize dose delivery in radiation therapy. IAEA has provided Postal Audit of Radiation Beam Dosimetry since 1969 to standardize treatment delivery. Medanta Cancer Institute offers the gold standard of internationally benchmarked radiation therapies to patients. Medanta Cancer Institute was among 15 centres worldwide to participate in the audit. It has successfully conducted 1,340 successful CyberKnife therapies and 780 Tomotherapy treatments till date.

Dr. Naresh Trehan, Chairman and Managing Director, Medanta said, ‘’I congratulate the team for passing the world-renowned Postal Dosimetry Audit and becoming the first organisation in India to receive this certification. Exercises such as this re-enforce our credo of delivering excellent radiation therapy treatment for all our patients.”

With the incidence of cancer cases rising exponentially, Radiation Oncology will play a crucial role in managing and curing cancer. Specialised treatment options such as CyberKnife and Tomotherapy that are non-invasive provide greater accuracy and minimise patient discomfort.

Speaking on the achievement, Dr. Tejinder Kataria, Chairperson, Radiation Oncology, Medanta Cancer Institute said, ‘We are proud to have cleared this internationally benchmarked quality assurance audit and hope to deliver radiation therapies of global standards to patients. We look forward to serving both national and international patients who need superlative care through world-class treatment under a single roof.’’


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account